Efficacy News and Research

RSS

Characterization of SARS-CoV-2 viral trajectory

In a study available on the preprint server medRxiv* researchers aimed to characterize early viral shedding in patients with incident infection. Read more here.

6 Sep 2021

Israeli study on viral load, Delta infections, vaccinations and boosters

Scientists from Israel have recently explored the effectiveness of two-dose and three-dose regimens of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine (Pfizer/BioNTech) to reduce viral load in breakthrough infections caused by the delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Sep 2021

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs regarding coronavirus disease (COVID-19). The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.

5 Sep 2021

Efficacy of vaccines against the SARS-CoV-2 Delta variant

A new study uses statistical models to determine vaccine efficacy against the various SARS-CoV-2 variants and clinical endpoints for SARS-CoV-2 variants.

5 Sep 2021

New diagnostic system can rapidly and sensitively measure antibodies against SARS-CoV-2

A research team at the RIKEN Center for Emergent Matter Science in Japan has developed a diagnostic system that can rapidly and sensitively measure the amount of antibodies in the blood that can protect us from SARS-CoV-2, the virus that causes COVID-19.

4 Sep 2021

Study highlights the impact of Mayo Clinic's COVID-19 Remote Patient Monitoring Program

A study by Mayo Clinic investigators highlights the development and implementation of Mayo Clinic's large-scale COVID-19 Remote Patient Monitoring Program, which has served more than 7,000 patients across 41 states.

4 Sep 2021

HIV vaccine candidate trialed in Sub-Saharan Africa falls short

An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organizers say.

4 Sep 2021

Immunological differences in Moderna and Pfizer-BioNTech vaccine-induced Fc-functional profiles

A new study analyzed the post-boost binding and functional capacity of the humoral response induced by the Pfizer-BioNTech and Moderna vaccines.

3 Sep 2021

Higher daily step count reduces mortality in middle-aged adults

Study shows that daily steps are associated with mortality from coronary artery disease in young adults.

3 Sep 2021

Third vaccine dose reduces transmission and severe COVID-19 nationwide in Israel

A new preprint investigates the efficacy of a booster vaccine on a nationwide scale in reducing viral spread and the number of severe COVID-19 cases.

3 Sep 2021

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.

3 Sep 2021

UCD spin-out company secures €595k in seed funding to advance drug development

BioSimulytics (www.biosimulytics.ai), a University College Dublin (UCD) spin-out company, today announced that it has secured €595k in initial seed funding from a number of strategic angel investors and Enterprise Ireland.

2 Sep 2021

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Chimeric antigen receptor (CAR) T cell therapy, which uses engineered T cells to treat certain types of cancers, has often been a challenging approach to treating solid tumors. CAR T cells need to recognize a specific target on cancer cells to kill them.

2 Sep 2021

Lack of information or misconceptions affect support for long-term disaster preparedness

As the 16th anniversary of Hurricane Katrina on Aug. 29 approached, New Orleans residents were bracing for another disaster, Hurricane Ida. This year, similar to last, the country will be hit by an above-average number of extreme weather events, including major hurricanes, flooding, and wildfires.

2 Sep 2021

Booster shot of Pfizer COVID-19 vaccine provides additional protection against SARS-CoV-2 infection

A team of scientists from the USA and Israel has recently highlighted the importance of a third booster dose of the Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine in achieving additional protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server.

2 Sep 2021

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

First-in-human trial proves feasibility of Temporally Feathered Radiation Therapy

Researchers from Cleveland Clinic and OhioHealth have published results from a first-in-human trial evaluating feasibility of Temporally Feathered Radiation Therapy (TFRT), which is designed to reduce the toxicity of radiation treatment.

1 Sep 2021

Can barrier gestures be relaxed without causing a COVID-19 resurgence in France?

A new study focused on determining the magnitudes of a barrier gesture relaxation in France. Read more here.

1 Sep 2021

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Burkitt lymphoma (BL) is a highly aggressive form of non-Hodgkin lymphoma (NHL) that comes in three different variants: endemic, immunodeficiency-associated, and sporadic. Of these variants, sporadic BL is most commonly found outside malaria-endemic countries and typically seen in young adults.

1 Sep 2021

Efficacy News and Research

Characterization of SARS-CoV-2 viral trajectory

Israeli study on viral load, Delta infections, vaccinations and boosters

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

Efficacy of vaccines against the SARS-CoV-2 Delta variant

New diagnostic system can rapidly and sensitively measure antibodies against SARS-CoV-2

Study highlights the impact of Mayo Clinic's COVID-19 Remote Patient Monitoring Program

HIV vaccine candidate trialed in Sub-Saharan Africa falls short

Immunological differences in Moderna and Pfizer-BioNTech vaccine-induced Fc-functional profiles

Higher daily step count reduces mortality in middle-aged adults

Third vaccine dose reduces transmission and severe COVID-19 nationwide in Israel

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

UCD spin-out company secures €595k in seed funding to advance drug development

CAR T cells expressing a natural RNA can activate the body’s own T cells against solid tumors

Lack of information or misconceptions affect support for long-term disaster preparedness

Booster shot of Pfizer COVID-19 vaccine provides additional protection against SARS-CoV-2 infection

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

First-in-human trial proves feasibility of Temporally Feathered Radiation Therapy

Can barrier gestures be relaxed without causing a COVID-19 resurgence in France?

Modified R-CODOX-M/IVAC regimen shows promise for treating sporadic Burkitt lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News